IMV Inc. (NASDAQ:IMV) detailed third quarter financial results before market open today.
The company unwinded loss for the third quarter of C$ 7.90 million or C$ 0.16 per share, compared to loss of C$ 5.99 million or C$ 0.14 per share for the year-ago quarter.
Topline results for the third quarter improved 23.08 percent to C$ 0.16 million from C$ 0.13 million in the same quarter last year
Frederic Ors, President and Chief Executive Officer of IMV, said, In the third quarter and more recently, we have continued to advance our pipeline forward. In particular, we were pleased to report preliminary data at ESMO that highlighted DPX-Survivacs potential to treat numerous solid tumors beyond our lead indications. Additionally, we launched a collaboration with The Wistar Institute, which applies our DPX-based targeted T cell therapy to the common BRAF mutation – another prevalent target across a range of tumor types.